Meanwhile, investors await key clinical data.
ApexOnco Front Page
Recent articles
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.